Found 830 clinical trials
Moderate to Severe Rheumatoid Arthritis (RA)
Adults with rheumatoid arthritis have an increased risk of blood clots. This research study is comparing the risk of blood clots among patients treated with certain study medications.  
- 10 views
- 23 Nov, 2020
- 1 location
Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy
Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy
- 114 views
- 08 Nov, 2020
- 1 location
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery
- 40 views
- 25 Mar, 2021
- 1 location
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab
- 0 views
- 02 Aug, 2021
- 50 locations
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis
A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
- 5 views
- 07 Sep, 2021
- 89 locations
adaptatiVe Endovascular Strategy to the CloT MRI in Large Intracranial Vessel Occlusion
case of friable, non-well organized, red blood cell rich (RBC) i.e. SVS + thrombi (25-28). This could, be related to worst clinical outcome at 3 months. VECTOR asks a relevant question: Do the
- 0 views
- 24 Jun, 2021
- 29 locations
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.
- 0 views
- 31 Jul, 2021
- 34 locations
A Study of BAX 930 in Children Teenagers and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich
- 3 views
- 19 Sep, 2021
- 44 locations